Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

Cited by (999)

Items 101–200 of 999

1. Prognostic impact and targeting of CRM1 in acute myeloid leukemia
   Kensuke Kojima, Steven Mitchell Kornblau, Vivian R. Ruvolo, Archana Dilip, Seshagiri R. Duvvuri, Richard Eric Davis, Min Zhang, Zhiqiang Wang, Kevin R. Coombes, Nianxiang Zhang et al. · 2013 · Blood
2. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype
   Frank Dicker, Hannes Herholz, Susanne Schnittger, Aki Nakao, Nancy Patten, Lin Wu, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach · 2008 · Leukemia
3. YB-1: oncoprotein, prognostic marker and therapeutic target?
   Annette Lasham, Cristin Gregor Print, Adele G. Woolley, Sandra Elaine Dunn, Antony W. Braithwaite · 2012 · Biochemical Journal
4. Chaperone-mediated autophagy degrades mutant p53
   Helin Vakifahmetoglu-Norberg, Minsu Kim, Hongguang Xia, Marcin Iwanicki, Dimitry Ofengeim, Jonathan L. Coloff, Lifeng Pan, Tan A. Ince, Guido Kroemer, Joan S. Brugge et al. · 2013 · Genes & Development
5. Prion-like aggregation of mutant p53 in cancer
   Jerson Lima Silva, C. V. de Moura Gallo, Danielly C. Ferraz da Costa, Luciana Pereira Rangel · 2014 · Trends in Biochemical Sciences
6. How to make a melanoma: what do we know of the primary clonal events?
   Dorothy C. Bennett · 2008 · Pigment Cell & Melanoma Research
7. p53 genes function to restrain mobile elements
   Annika Wylie, Amanda E. Jones, Alejandro D’Brot, Wan-Jin Lu, Paula Kurtz, John V. Moran, Dinesh Rakheja, Kenneth Sung-Man Chen, Robert E. Hammer, Sarah A. Comerford et al. · 2015 · Genes & Development
8. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections
   Maria Lina Tornesello, Luigi Buonaguro, Fabiana Tatangelo, Gerardo Botti, Francesco Izzo, Luigi Buonaguro · 2013 · Genomics
9. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol
   Funda Meric‐Bernstam, Lauren Brusco, Molly S. Daniels, Chetna Wathoo, Ann Marie Bailey, Louise C. Strong, Kenna R Mills Shaw, Karen H. Lu, Yuan Qi, Hao Zhao et al. · 2016 · Annals of Oncology
10. Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils
    Alexander H. Stegh · 2012 · Expert Opinion on Therapeutic Targets
11. p53 Proteoforms and Intrinsic Disorder: An Illustration of the Protein Structure–Function Continuum Concept
    Vladimir Nikolaevich Uversky · 2016 · International Journal of Molecular Sciences
12. Genotoxicity: damage to DNA and its consequences
    David H. Phillips, Volker Manfred Arlt · 2009 · Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions
13. C. eleganswhole-genome sequencing reveals mutational signatures related to carcinogens and DNA repair deficiency
    Bettina Meier, Susanna L. Cooke, Joerg Weiss, Aymeric Bailly, Ludmil B. Alexandrov, John Marshall, Keiran M. Raine, Mark Maddison, Elizabeth L. Anderson, Michael R. Stratton et al. · 2014 · Genome Research
14. MEG3: an Oncogenic Long Non-coding RNA in Different Cancers
    Arwa Al-Rugeebah, Mohammed Alanazi, Narasimha Reddy Parine · 2019 · Pathology & Oncology Research
15. Contribution of reactive oxygen species to ovarian cancer cell growth arrest and killing by the anti-malarial drug artesunate
    Anna L. Greenshields, Trevor G. Shepherd, David W. Hoskin · 2016 · Molecular Carcinogenesis
16. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia
    Šárka Pospı́šilová, David González de Castro, Jitka Malčíková, Martin Trbušek, Davide Rossi, Arnon Philip Kater, Florence Cymbalista, Barbara F. Eichhorst, Michael J. Hallek, Hartmut Döhner et al. · 2012 · Leukemia
17. Metastatic pancreatic cancer is dependent on oncogenic Kras in mice
    Collins, Meredith A., Brisset, Jean-Christophe, Zhang, Yaqing, Bednar, Filip, Pierre, Josette, Heist, Kevin A., Galbán, Craig J., Galbán, Stefanie, di Magliano, Marina Pasca · 2012 · PLoS ONE
18. p53-dependent Induction of PVT1 and miR-1204
    Anthony M. Barsotti, Rachel Beckerman, Oleg Laptenko, Konrad E. Huppi, Natasha J. Caplen, Carol L. Prives · 2011 · Journal of Biological Chemistry
19. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage
    Jitka Malčíková, Jana Šmardová, Ludmila Ročňová, Boris Tichý, Petr Kuglík, Vladimíra Vranová, Soňa Čejková, Miluše Svitáková, Hana Skuhrová Francová, Yvona Brychtová et al. · 2009 · Blood
20. Hallmarks of glioblastoma: a systematic review
    Dorte Schou Nørøxe, Hans Skovgaard Poulsen, Ulrik Lassen · 2016 · ESMO Open
21. Whole-exome sequencing identifies multiple loss-of-function mutations of NF-κB pathway regulators in nasopharyngeal carcinoma
    Hong Zheng, Wei Dai, Arthur Kwok Leung Cheung, Josephine Mun Yee Ko, Rebecca Kan, Bonnie Wing Yan Wong, Merrin Man‐Long Leong, Mingdan Deng, Tommy Chin Tung Kwok, Jimmy Yu Wai Chan et al. · 2016 · Proceedings of the National Academy of Sciences
22. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies
    Zijun Yidan Xu-Monette, Leonard Jeffrey Medeiros, Yong Li, Robert Zygmunt Orlowski, Michael Andreeff, Carlos Bueso-Ramos, Timothy C. Greiner, Timothy J. McDonnell, Ken H. Young · 2012 · Blood
23. Senescence Regulation by the p53 Protein Family
    Yingjuan Qian, Xinbin Chen · 2012 · Methods in molecular biology
24. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells
    Twee Tsao, Yuexi Shi, Steven Mitchell Kornblau, Hongbo Lu, Sergej Naumovich Konoplev, Ansu Antony, Vivian R. Ruvolo, Yi Hua Qiu, Ninaxiang Zhang, Kevin R. Coombes et al. · 2012 · Annals of Hematology
25. High Incidence of Protein-Truncating TP53 Mutations in BRCA1-Related Breast Cancer
    Henne H. Holstege, Simon Andreas Joosse, Conny Th.M. van Oostrom, Petra M. Nederlof, Annemieke de Vries, Jos Jonkers · 2009 · Cancer Research
26. An Illegitimate microRNA Target Site within the 3′ UTR of MDM4 Affects Ovarian Cancer Progression and Chemosensitivity
    Jessika Wynendaele, Anja Böhnke, Eleonora Leucci, Søren Jensby Nielsen, Irina Lambertz, Stefanie Hammer, Nadja Sbrzesny, Dana Kubitza, Anja A. Wolf, Elise Gradhand et al. · 2010 · Cancer Research
27. APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
    Peng, X, Zhang, M-Q-Z, Conserva, F, Hosny, G, Selivanova, G, Bykov, V J N, Arnér, E S J, Wiman, K G · 2013 · Cell Death & Disease
28. The many faces of p53: something for everyone
    Levine, Arnold J · 2019 · Journal of Molecular Cell Biology
29. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations
    Jordi Remón, Francesco Passiglia, Myung‐Ju Ahn, Fabrice Barlési, Patrick M. Forde, Edward B. Garon, Scott N. Gettinger, Sarah B. Goldberg, Roy S. Herbst, Leora Horn et al. · 2020 · Journal of Thoracic Oncology
30. Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies
    Ido Goldstein, Virginie Marcel, Magali Olivier, Moshe Oren, Varda Rotter, Pierre L. Hainaut · 2010 · Cancer Gene Therapy
31. Pro-proliferative FoxM1 is a target of p53-mediated repression
    Anthony M. Barsotti, Carol L. Prives · 2009 · Oncogene
32. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53
    Gemma L. Kelly, Stephanie Grabow, Stefan P. Glaser, Leah Fitzsimmons, Brandon J. Aubrey, Toru Okamoto, Liz J. Valente, Mikara Robati, Lin Tai, Walter Douglas Fairlie et al. · 2014 · Genes & Development
33. Reactive Oxygen Species Induced p53 Activation: DNA Damage, Redox Signaling, or Both?
    Tao Shi, Tobias B. Dansen · 2020 · Antioxidants and Redox Signaling
34. The TP53 Database: transition from the International Agency for Research on Cancer to the US National Cancer Institute
    Kelvin C. de Andrade, Elaine E. Lee, Elise M. Tookmanian, Chimene A. Kesserwan, James J. Manfredi, Jessica N. Hatton, Jennifer K. Loukissas, Jiří Zavadil, Lei Ji Zhou, Magali Olivier et al. · 2022 · Cell Death and Differentiation
35. Recent advances in p53 research: an interdisciplinary perspective
    Magali Olivier, Audrey Petitjean, Virginie Marcel, Aurélia Pétré, Mounia Mounawar, Amelie Plymoth, Claude Caron de Fromentel, Pierre L. Hainaut · 2008 · Cancer Gene Therapy
36. Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer
    David M. Neskey, Abdullah A. Osman, Thomas Julian Ow, Panagiotis Katsonis, Thomas O. McDonald, Stephanie C. Hicks, Teng‐Kuei Hsu, Curtis R. Pickering, Alexandra M. Ward, Ameeta A. Patel et al. · 2015 · Cancer Research
37. Germline TP53 Variants and Susceptibility to Osteosarcoma
    Mirabello, Lisa, Yeager, Meredith, Mai, Phuong L., Gastier-Foster, Julie M., Gorlick, Richard, Khanna, Chand, Patiño-Garcia, Ana, Sierrasesúmaga, Luis, Lecanda, Fernando, Andrulis, Irene L. et al. · 2015 · JNCI Journal of the National Cancer Institute
38. Identification of a Novel TP53 Cancer Susceptibility Mutation Through Whole-Genome Sequencing of a Patient With Therapy-Related AML
    Daniel C. Link · 2011 · JAMA
39. Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer
    José J.G. Marı́n, Fermín Sánchez de Medina, Beatriz Castaño, Luís Bujanda, Marta R. Romero, Olga Martínez‐Augustin, Rosario del Moral-Ávila, Óscar Briz · 2012 · Drug Metabolism Reviews
40. Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues
    Jeffrey D. Krimmel‐Morrison, Michael W. Schmitt, Maria I. Harrell, Kathy J. Agnew, Scott R. Kennedy, Mary Jane Emond, Lawrence A. Loeb, Elizabeth M. Swisher, Rosa Ana Risques · 2016 · Proceedings of the National Academy of Sciences
41. Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect
    Garritano, Sonia, Gemignani, Federica, Palmero, Edenir Inez, Olivier, Magali, Martel-Planche, Ghyslaine, Le Calvez-Kelm, Florence, Brugiéres, Laurence, Vargas, Fernando Regla, Brentani, Ricardo Renzo, Ashton-Prolla, Patricia et al. · 2010 · Human Mutation
42. GermlineTP53Mutations and the Changing Landscape of Li-Fraumeni Syndrome
    Junne Kamihara, Huma Q. Rana, Judy Ellen Garber · 2014 · Human Mutation
43. Drugging the addict: non‐oncogene addiction as a target for cancer therapy
    Remco Nagel, Ekaterina A Semenova, Anton J. M. Berns · 2016 · EMBO Reports
44. Association of TP53 Mutations With Stem Cell-Like Gene Expression and Survival of Patients With Hepatocellular Carcinoma
    Hyun Goo Woo, Xin Wei Wang, Anuradha Budhu, Yun Hee Kim, So Mee Kwon, Zhao–You Tang, Zongtang Sun, Curtis C. Harris, Snorri S. Thorgeirsson · 2010 · Gastroenterology
45. The aflatoxin-induced TP53 mutation at codon 249 (R249S): Biomarker of exposure, early detection and target for therapy
    Doriane A. Gouas, Hong Shi, Pierre L. Hainaut · 2009 · Cancer Letters
46. Malignant Melanoma in the 21st Century: The Emerging Molecular Landscape
    Aleksandar Sekulić, Paul Haluska, Arlo J. Miller, Josep Genebriera De Lamo, Samuel Ejadi, José S. Pulido, Diva R. Salomão, Erik C. Thorland, Richard G. Vile, David C. Swanson et al. · 2008 · Mayo Clinic Proceedings
47. Accumulation of Somatic Mutations in TP53 in Gastric Epithelium With Helicobacter pylori Infection
    Takahiro Shimizu, Hiroyuki Marusawa, Yuko Mizuno Matsumoto, Tadashi Inuzuka, Atsuyuki Ikeda, Yosuke Fujii, Sachiko Minamiguchi, Shin’ichi Miyamoto, Tadayuki Kou, Yoshiharu Sakai et al. · 2014 · Gastroenterology
48. The Conundrum of Genetic “Drivers” in Benign Conditions
    Shumei Kato, Scott Michael Lippman, Keith T. Flaherty, Razelle Kurzrock · 2016 · JNCI Journal of the National Cancer Institute
49. Revisiting TP 53 Mutations and Immunohistochemistry—A Comparative Study in 157 Diffuse Gliomas
    Hirokazu Takami, Akihiko Yoshida, Shintaro Fukushima, Hideyuki Arita, Yuko Matsushita, Taishi Nakamura, Makoto Ohno, Yasuji Miyakita, Soichiro Shibui, Yoshitaka Narita et al. · 2014 · Brain Pathology
50. Structural evolution of p53, p63, and p73: Implication for heterotetramer formation
    Andreas C. Joerger, S. Rajagopalan, Eviatar Natan, Dmitry B. Veprintsev, Carol V. Robinson, Alan Roy Fersht · 2009 · Proceedings of the National Academy of Sciences
51. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases
    Chi Young Ok, Keyur Pravinchandra Patel, Guillermo Garcia‐Manero, Mark J. Routbort, Jie Peng, Guilin Tang, Maitrayee Goswami, Ken H. Young, Rajesh R. Singh, Leonard Jeffrey Medeiros et al. · 2015 · Journal of Hematology & Oncology
52. NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma
    Zhao, S, Kurenbekova, L, Gao, Y, Roos, A, Creighton, C J, Rao, P, Hicks, J, Man, T-K, Lau, C, Brown, A M C et al. · 2015 · Oncogene
53. Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations
    Luciano Gastón Martelotto, Charlotte K.Y. Ng, Maria Rosaria De Filippo, Yan Zhang, Salvatore Piscuoglio, Raymond S. Lim, Ronglai Shen, Larry Norton, Jorge Sergio Reis-Filho, Britta Weigelt · 2014 · Genome biology
54. High resolution melting for mutation scanning of TP53exons 5–8
    Michael Krypuy, Ahmed A. Ahmed, Dariush Etemadmoghadam, Sarah J. Hyland, Georgia Chenevix‐Trench, Anna DeFazio, Stephen B. Fox, James D. Brenton, David D.L. Bowtell, Alexander Dobrovic · 2007 · BMC Cancer
55. Single nucleotide variations: Biological impact and theoretical interpretation
    Panagiotis Katsonis, Amanda M. Koire, Stephen Joseph Wilson, Teng‐Kuei Hsu, Rhonald C. Lua, Angela D. Wilkins, Olivier Lichtarge · 2014 · Protein Science
56. A formal perturbation equation between genotype and phenotype determines the evolutionary action of protein-coding variations on fitness
    Katsonis, Panagiotis, Lichtarge, Olivier · 2014 · Genome Research
57. Early onset HER2‐positive breast cancer is associated with germline TP53 mutations
    Amal Melhem‐Bertrandt, Jasmina Bojadzieva, Kaylene J. Ready, Elias I. Obeid, Diane D. Liu, Angelica M. Gutierrez‐Barrera, Jennifer Keating Litton, Olufunmilayo Ibironke Olopade, Gabriel N. Hortobágyi, Louise C. Strong et al. · 2011 · Cancer
58. TP53 Mutations and Pathologic Complete Response to Neoadjuvant Cisplatin and Fluorouracil Chemotherapy in Resected Oral Cavity Squamous Cell Carcinoma
    Federica Perrone, Paolo Bossi, Barbara Cortelazzi, Laura D. Locati, Pasquale Quattrone, Marco Alessandro Pierotti, Silvana Pilotti, Lisa Francesca Licitra · 2010 · Journal of Clinical Oncology
59. The disulfide compound α-lipoic acid and its derivatives: A novel class of anticancer agents targeting mitochondria
    Bastian Dörsam, Jörg Fahrer · 2015 · Cancer Letters
60. Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers
    Simone Hettmer, Natasha M. Archer, Gino R. Somers, Ana Novokmet, Amy J. Wagers, Lisa Diller, Carlos Rodriguez Galindo, Lisa A. Teot, David M. Malkin · 2013 · Cancer
61. Erratum: APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
    Xiaoxiao Peng, Meiqiongzi Zhang, Francesca Conserva, Gihan Hosny, Galina Selivanova, Vladimir J.N. Bykov, Elias S.J. Arnér, Klas G. Wiman · 2017 · Cell Death and Disease
62. Differentiated vulvar intraepithelial neoplasia contains Tp53 mutations and is genetically linked to vulvar squamous cell carcinoma
    Álvaro P. Pinto, Alexander Miron, Yosuf Yassin, Nicolas M. Monte, Terri Y C Woo, Karishma K. Mehra, Fabíola Medeiros, Christopher P. Crum · 2010 · Modern Pathology
63. Repurposing CRISPR/Cas9 for in situ functional assays
    Abba Malina, John R. Mills, Regina Cencic, Yifei Yan, James Fraser, Laura M. Nederveen-Schippers, Marilène Paquet, Josée Dostie, Jerry Pelletier · 2013 · Genes & Development
64. Molecular Mechanism of Mutant p53 Stabilization: The Role of HSP70 and MDM2
    Milena Wiech, Maciej B. Olszewski, Zuzanna Tracz‐Gaszewska, Bartosz Wawrzynów, Maciej Żylicz, Maciej Żylicz · 2012 · PLoS ONE
65. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation
    Yongxing Wang, Young‐Ah Suh, Maren Y. Fuller, James G. Jackson, Shunbin Xiong, Tamara Terzian, Alfonso Quintás‐Cardama, James A. Bankson, Adel K. El‐Naggar, Guillermina Lozano · 2011 · Journal of Clinical Investigation
66. Δ160p53 is a novel N‐terminal p53 isoform encoded by Δ133p53 transcript
    Virginie Marcel, Stéphane Perrier, Mustapha Aoubala, Sylvain Ageorges, Michael J. Groves, Alexandra Diot, Kenneth Fernandes, Sudhir Tauro, Jean‐Christophe Bourdon · 2010 · FEBS Letters
67. TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers
    Anne Maria Schultheis, Luciano Gastón Martelotto, Maria Rosaria De Filippo, Salvatore Piscuglio, Charlotte K.Y. Ng, Yaser R. Hussein, Jorge Sergio Reis-Filho, Robert A. Soslow, Britta Weigelt · 2015 · International Journal of Gynecological Pathology
68. TP53mutations, expression and interaction networks in human cancers
    Xiaosheng Wang, Qingrong Sun · 2016 · Oncotarget
69. Identifying breast cancer susceptibility genes – a review of the genetic background in familial breast cancer
    Camilla Wendt, Sara Margolin · 2019 · Acta Oncologica
70. p53 as a hub in cellular redox regulation and therapeutic target in cancer
    Eriksson, Sofi E, Ceder, Sophia, Bykov, Vladimir J N, Wiman, Klas G · 2019 · Journal of Molecular Cell Biology
71. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior
    Francesco Forconi, Elisa Sozzi, Emanuele Cencini, Francesco F. Zaja, Tamara Intermesoli, Caterina Cecilia Stelitano, Luigi Rigacci, Filíppo Gherlinzoni, Renato Cantaffa, Anna Baraldi et al. · 2009 · Blood
72. A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours
    Maja J.A. de Jonge, Vincent A. de Weger, Mark Andrew Dickson, Marlies H.G. Langenberg, Axel Le Cesne, Andrew J. Wagner, Karl Hsu, Wei Zheng, Sandrine Macé, Gilles Tuffal et al. · 2017 · European Journal of Cancer
73. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival
    Derville O’Shea, Ciarán Ó’Riain, Claire Taylor, Rachel Waters, Emanuela Carlotti, Finlay MacDougall, John G. Gribben, Andreas Rosenwald, German Ott, Lisa M. Rimsza et al. · 2008 · Blood
74. The Human TLR Innate Immune Gene Family Is Differentially Influenced by DNA Stress and p53 Status in Cancer Cells
    Shatz, Maria, Menendez, Daniel, Resnick, Michael A. · 2012 · Cancer Research
75. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial
    Herve R. Bonnefoi, Martine J Piccart, Jan Bogaerts, L. Mauriac, P. Fumoleau, Etienne G.C. Brain, Thierry Petit, Philippe Rouanet, Jacek Jassem, Emmanuel Blot et al. · 2011 · The Lancet Oncology
76. Field Cancerization in the Intestinal Epithelium of Patients With Crohn's Ileocolitis
    Susan Galandiuk, Manuel Rodriguez‐Justo, Rosemary E. Jeffery, Anna M. Nicholson, Yong Cheng, Dahmane Oukrif, George Elia, Simon John Leedham, Stuart A.C. McDonald, Nicholas A. Wright et al. · 2011 · Gastroenterology
77. DNA Sequence Profiles of the Colorectal Cancer Critical Gene Set KRAS-BRAF-PIK3CA-PTEN-TP53 Related to Age at Disease Onset
    Marianne Berg, Stine Aske Danielsen, Terje C. Ahlquist, Marianne A. Merok, Trude H. Ågesen, Morten Harald Vatn, Tom Mala, Ole Helmer Sjo, Arne Olav Bakka, Ingvild Ona Moberg et al. · 2010 · PLoS ONE
78. CHASMplus Reveals the Scope of Somatic Missense Mutations Driving Human Cancers
    Collin J. Tokheim, Rachel Karchin · 2019 · Cell Systems
79. The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies
    Julie Earl, Daniel Rico, Enrique Carrillo de Santa Pau, Benjamín Rodríguez‐Santiago, Marinela Méndez‐Pertuz, Herbert Auer, Gonzalo Goméz-López, Herbert Barton Grossman, David G. Pisano, Wolfgang A. Schulz et al. · 2015 · BMC Genomics
80. Tetramer formation of tumor suppressor protein p53: Structure, function, and applications
    Rui Kamada, 侑 戸口, Takao Nomura, Toshiaki Imagawa, Kazuyasu Sakaguchi · 2015 · Biopolymers
81. Defining actionable mutations for oncology therapeutic development
    Thomas Hedley Carr, Robert K. McEwen, Brian Andrew Dougherty, Justin H. Johnson, Jonathan R. Dry, Zhongwu Lai, Zara F. Ghazoui, Naomi M. Laing, Darren Hodgson, Francisco H. Cruzalegui et al. · 2016 · Nature reviews. Cancer
82. p53 tetramerization: at the center of the dominant-negative effect of mutant p53
    Jovanka Gencel‐Augusto, Guillermina Lozano · 2020 · Genes & Development
83. A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations: Table 1
    Wilson, J R F, Bateman, A C, Hanson, H, An, Q, Evans, G, Rahman, N, Jones, J L, Eccles, D M · 2010 · Journal of Medical Genetics
84. Long noncoding RNA lincRNA-p21 is the major mediator of UVB-induced and p53-dependent apoptosis in keratinocytes
    Jonathan R. Hall, Zachary J. Messenger, Hann W. Tam, S. Phillips, Leslie Recio, Robert C. Smart · 2015 · Cell Death and Disease
85. Li‐Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition
    Jessica M. Valdez, Kim E. Nichols, Chimene A. Kesserwan · 2016 · British Journal of Haematology
86. p53 N-terminal phosphorylation: a defining layer of complex regulation
    Lisa M. Miller Jenkins, Stewart R. Durell, Sharlyn J. Mazur, Ettore Appella · 2012 · Carcinogenesis
87. Phosphosignature predicts dasatinib response in non-small cell lung cancer
    Klammer, Martin, Kaminski, Marc, Zedler, Alexandra, Oppermann, Felix, Blencke, Stephanie, Marx, Sandra, Müller, Stefan, Tebbe, Andreas, Godl, Klaus, Schaab, Christoph · 2012 · Molecular & Cellular Proteomics
88. Molecular genetics of syndromic and non-syndromic forms of parathyroid carcinoma
    Luís Cardoso, Mark Stevenson, Rajesh V. Thakker · 2017 · Human Mutation
89. Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms
    Zeinab Safarpour Lima, Mostafa Ghadamzadeh, Farzad Tahmasebi Arashloo, Ghazaleh Amjad, Mohammad Reza Ebadi, Ladan Younesi · 2019 · Journal of Hematology & Oncology
90. Computer-aided drug repurposing for cancer therapy: Approaches and opportunities to challenge anticancer targets
    Carla Mottini, Francesco Napolitano, Zhongxiao Li, Xin Gao, Luca Cardone · 2019 · Seminars in Cancer Biology
91. Metabolic characterization of cell systems used in in vitro toxicology testing: Lung cell system BEAS-2B as a working example
    Carolina Garcia‐Canton, Emmanuel Minet, Arturo Anadón, Clive Meredith · 2013 · Toxicology in Vitro
92. Targeted next generation sequencing of breast implant‐associated anaplastic large cell lymphoma reveals mutations in JAK / STAT signalling pathway genes, TP 53 and DNMT 3A
    Arianna Di Napoli, Preti Jain, Enrico Duranti, Elizabeth Michelle Margolskee, Walter Arancio, Fabio Facchetti, Bachir Alobeid, Fabio Santanelli di Pompeo, MAHESH M. MANSUKHANI, Govind Bhagat · 2016 · British Journal of Haematology
93. p53: The barrier to cancer stem cell formation
    Ronit Aloni-Grinstein, Yoav Shetzer, Tom Kaufman, Varda Rotter · 2014 · FEBS Letters
94. Toward the Rational Design of p53-Stabilizing Drugs: Probing the Surface of the Oncogenic Y220C Mutant
    Nicolas Basse, Joel L. Kaar, Giovanni Settanni, Andreas C. Joerger, Trevor J. Rutherford, Alan Roy Fersht · 2010 · Chemistry & Biology
95. Prognostic value ofTP53,KRASandEGFRmutations in nonsmall cell lung cancer: the EUELC cohort
    Chiara Scoccianti, Aurélien Vesin, Ghislaine Martel, Magali Olivier, Elisabeth M. Brambilla, JF Timsit, Luca Tavecchio, Christian Brambilla, John K. Field, Pierre L. Hainaut · 2012 · European Respiratory Journal
96. m5C RNA Methylation Regulators Predict Prognosis and Regulate the Immune Microenvironment in Lung Squamous Cell Carcinoma
    Junfan Pan, Zhidong Huang, Yiquan Xu · 2021 · Frontiers in Oncology
97. Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and MDM2 Amplification in Sarcomagenesis
    Ito, Moriko, Barys, Louise, O'Reilly, Terence, Young, Sophie, Gorbatcheva, Bella, Monahan, John, Zumstein-Mecker, Sabine, Choong, Peter F., Dickinson, Ian, Crowe, Philip et al. · 2011 · Clinical Cancer Research
98. p53 Modulates Acquired Resistance to EGFR Inhibitors and Radiation
    Shyhmin Huang, Sergi Benavente, Eric A. Armstrong, Chunrong Li, Deric L. Wheeler, Paul M. Harari · 2011 · Cancer Research
99. CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer
    Melania Zauri, G. Berridge, Marie‐Laëtitia Thézénas, Kathryn Pugh, Robert David Goldin, Benedikt Mathias Kessler, Skirmantas Kriaučionis · 2015 · Nature
100. Interactions between the tumor suppressor p53 and immune responses
     Daniel Menéndez, Maria Shatz, Michael A. Resnick · 2012 · Current Opinion in Oncology